

IDEXX LABORATORIES INC /DE
Form 4
August 11, 2010

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
RAINES MERILEE

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE
[IDXX]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

(Last) (First) (Middle)
ONE IDEXX DRIVE
(Street)

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2010

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
Corporate VP & CFO

WESTBROOK, ME 04092

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | Code | V | Amount | (D) | Price |
| Common Stock | 08/10/2010 | | M | | 10,578 | A | \$ 11.3438 |
| Common Stock | 08/10/2010 | | M | | 16,000 | A | \$ 13.315 |
| Common Stock | 08/10/2010 | | M | | 29,422 | A | \$ 11.3438 |
| Common Stock | 08/10/2010 | | S | | 31,500 | D | \$ 59.0175 |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$58.82 to \$59.39, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.

- (2) Grant of options to buy shares of common stock becomes exercisable as to 2,578 shares on 2/7/2005 and 8,000 shares on 2/7/2006.
- (3) Grant of options to buy shares of common stock becomes exercisable as to 8,000 shares on 2/12/2003, 2/12/2004 and 2/12/2005, 7,306 shares on 2/12/2006, and the remaining 490 shares on 2/12/2007.
- (4) Grant of options to buy shares of common stock becomes exercisable as to 8,000 shares on 2/7/2002, 2/7/2003 and 2/7/2004, and the remaining 5,422 shares on 2/7/2005.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.